Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)
Status:
Completed
Trial end date:
2017-10-26
Target enrollment:
Participant gender:
Summary
Determine the PK and safety and tolerability of aztreonam-avibactam (ATM-AVI) in the
treatment of hospitalized adults with cIAI
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca Pfizer
Collaborators:
Centre Hospitalier Universitaire de Limoges, CHUL, France Clinical Trial Centre, Cologne, CTCC, Germany Innovative Medicines Initiative (IMI) COMBACTE-CARE Institute National de la Santé et de la Recherche Médicale, INSERM, France Servicio Andaluz de Salud, SAS, Spain Universitätsklinikum Köln, UKK, Germany University Medical Centre Utrecht, UMCU, the Netherlands